A 1950s antibiotic still beats resistance by barely entering the bloodstream
Nitrofurantoin has treated bladder infections since 1953, yet bacteria rarely learn to dodge it. Its secret is location: after a standard 100 mg dose, blood levels stay under 1 microgram per millilitre while urine reaches 200 or more. Inside bacteria it breaks into reactive fragments that attack many targets at once.
A preparation method was patented in 1952 and the drug went on sale the following year. The WHO counts it among essential drugs, it is sold as a generic, and in 2023 ranked 143rd among American prescriptions with more than 3 million filled. Rising resistance to other common agents, such as trimethoprim-sulfamethoxazole and fluoroquinolones, has renewed interest, and both American and European infectious disease societies list it as a first-line choice for uncomplicated urinary tract infections.
Its chemistry explains its durability. Bacterial flavoproteins called nitrofuran reductases rapidly convert the drug into reactive intermediates that damage DNA, ribosomal proteins, respiration and metabolism. Because it hits so many processes, resistance develops slowly, and acquired resistance in E. coli remains rare. Bacteria activate it faster than human cells do, which gives it some selectivity. At the concentrations found in urine it kills bacteria outright; at lower levels it merely stalls their growth.
The same concentration trick sets its limits. Tissue penetration is negligible, so it is not used for kidney infections, abscesses or chronic prostate infections. Meta-analyses report clinical cure rates of 79 to 92 percent, with a five-day course outperforming three days and matching a single dose of fosfomycin. Because it relies on the kidneys to reach the bladder, reduced kidney function can leave urine levels too low while blood levels climb.
Common side effects are nausea, headache and flatulence. Rare but serious reactions include lung inflammation, estimated at about one in 5000 women for the acute form, liver injury and nerve damage. It is not given to babies under one month or to people with G6PD deficiency because of the risk of red cell breakdown, and use near delivery is avoided. An old claim that it causes disulfiram-like reactions with alcohol failed to replicate and is now considered wrong.
Source: Nitrofurantoin
